Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
The findings, based on data from more than 800 TAVR patients, suggest that skipping OAC medications for a small amount of time could make a big impact.
“No clear recommendation currently exists in U.S. or European guidelines for performing PCI in addition to TAVR,” researchers wrote. The group hoped its study could provide some clarity.
According to new MODULAR ATP data, the leadless system was associated with a high success rate and few complications. Boston Scientific plans on seeking FDA approval in 2025.
Complications are also down after SAVR, researchers noted, though the drop has been much more dramatic for TAVR patients. The new analysis was based on Medicare data from more than 210,000 patients.
Should patients stay on beta-blockers more than one year after a heart attack? The team behind the ABYSS clinical trial explored that very question, presenting its data at ESC Congress 2024.